Fezolinetant

Fezolinetant has been studied in 54 papers since 2022: 9 trials and 1 observational study in people, 1 in animals, 42 reviews; 31 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Non-hormonal management of menopause symptoms—the statement of the European Society of Gynecology”.

InterventionApproved 2023

54 papers study it6 more mention it53 findingsUpdated

PubChemChEBIMeSH

8 new papers in 30 daysSee all 60 papers on fezolinetant

At a glance

Fezolinetant reduces menopausal vasomotor symptoms in human trials, with independent labs reproducing the reduction; a review finds no clear difference versus hormone therapies. Trials report improved sleep, while adverse-event results differ. Aging-related trials are registered; across uses, most trials have developer sponsors and some ended over a year ago without posted results, while human papers declare developer ties.

53 findings in 34 papers from 2023 to 2026, 14 of them since April 2026

Independent labs found the same change in people. 14 independent labs in 10 countries; 25 trials, 16 about aging, 9 with no results posted.

“reductions in VMS frequency for fezolinetant 45 mg versus placebo were - 1.46 (-2.01, -0.92) and - 2.51 (-3.20, -1.82).”
Early onset, maintenance of effect, and day-/night-time findings following fezolinetant treatment for moderate to severe vasomotor symptoms associated with menopause: A pooled phase 3 analysisMaturitas2025doi:10.1016/j.maturitas.2025.108740

3 of its findings point the other way.

Humans: replicated by independent labs. Worms or flies: a single group. Cells and mice: nothing yet.
  • 14 independent labs in 10 countries
  • 3 findings against
  • 25 trials, 16 about aging, 9 with no results posted
  • Funders: Astellas Pharma and others
  • 16 of 31 findings with company ties
  • 21 of 25 trials sponsored by its developers
  • Human trial9
  • Humans1
  • Model organisms1
  • In silico1

Studies in people

5 studies gave fezolinetant to people and measured what changed.

What changedDesignPeopleSource

up: Improves sleep disturbanceLS mean difference -1.31, 95% CI -2.59, -0.02

Randomized trial12 weeks1,022 peoplewomenmean age 54.3 ± 5.0 yearsPostmenopausal women seeking treatment or relief for vasomotor symptoms due to menopauseClimacteric : the journal of the International Menopause Society, Sep 14, 2026

down: Decreases hot flashes

down: Decreases depression

Randomized trial6 monthsWomen40-65 years oldMidlife adults; Older adults; Postmenopausal women; associated with menopauseWomen's health (London, England), Apr 3, 2026

down: Decreases work productivity loss22.6 vs 6.3 percentage points

down: Decreases missed work hours2.8 to 4.2 work hours per week per woman

Randomized trial1 yearwomenmean age of 53.8 yearsEmployed women from the SKYLIGHT 1 and 2 trials with moderate to severe VMS associated with menopauseMenopause (New York, N.Y.), Mar 31, 2026

down: Decreases vasomotor symptom frequencyWeek 12 least squares mean difference −2.51 (95% CI −3.20 to −1.82)

Randomized trial12 weeks1,022 peopleWomen≥40-≤65 yearsMidlife adults; Older adults; moderate to severe vasomotor symptoms associated with menopauseMaturitas, Oct 6, 2025

down: Decreases daily frequency of moderate-severe vasomotor symptomsLeast squares mean difference -1.93, 95% CI -2.64 to -1.22

down: Decreases sleep disturbancePROMIS SD-SF 8b total score difference -2.5, 95% CI -3.9 to -1.1; P<0.001

no change: Has no effect on treatment-emergent adverse eventsTEAEs: 65.0% versus 61.1%; serious TEAEs: 4.4% versus 3.5%

Randomized trial24 weeks452 people40-65 yearsMidlife adults; Menopause; unsuitable for hormone therapyBMJ (Clinical research ed.), Nov 18, 2024

What did studies of fezolinetant find?

21

Studies of fezolinetant measured 21 outcomes; the most studied are vasomotor symptoms (9 studies), vasomotor symptoms (7) and vasomotor symptom frequency (3).

Vasomotor symptoms

downin humans6upin humans3

9 studies
  1. Fezolinetant decreases vasomotor symptoms in humans (moderate to severe vasomotor symptoms due to menopause).

    “Fezolinetant reduced moderate to severe VMS due to menopause”

    Human trialmoderate to severe vasomotor symptoms due to menopause1 year

    Effect of fezolinetant on sleep, health-related quality of life and work productivity

    Climacteric : the journal of the International Menopause Society

  2. Fezolinetant decreases vasomotor symptoms in humans (menopause).

    “newly Food and Drug Administration (FDA)-approved NK3 receptor antagonists (e.g., fezolinetant), and structured plant-based dietary restructuring—offer substantial symptom reduction.”

    Reviewmenopause

    Contemporary Management of Menopausal Vasomotor Symptoms: An Evidence-Based Review of Hormonal and Non-Hormonal Interventions

    Clinical and Experimental Obstetrics & Gynecology

  3. Fezolinetant decreases vasomotor symptoms in humans (menopausal VMS in the general population).

    “Fezolinetant, a selective NK3 receptor antagonist approved for menopausal VMS in the general population, has shown robust efficacy across multiple phase III trials”

    Reviewmenopausal VMS in the general population

    Neurokinin pathway antagonists for vasomotor symptoms in women with breast cancer: focus on elinzanetant and fezolinetant

    Breast (Edinburgh, Scotland)

  4. Fezolinetant decreases vasomotor symptoms in humans.

    “Fezolinetant, a selective NK 3 receptor antagonist, and elinzanetant, a dual NK1/NK3 receptor antagonist, provide rapid and clinically meaningful reductions in VMS”

    Review

    Neurokinin 3 Receptor Antagonists for Menopause Symptom Management

    Obstetrics and gynecology clinics of North America

  5. Fezolinetant decreases vasomotor symptoms in patients with absolute contraindications to MHT.

    “the approval of neurokinin-3 (NK3) receptor antagonists (fezolinetant and elinzanetant) represents a paradigm shift in mitigating VMS via direct hypothalamic modulation”

    Reviewin patients with absolute contraindications to MHT

    Precision Pharmacological Stratification and Targeted Management of Pathological Menopause: Evidence-Based Hormone Replacement Therapy Optimization, Non-Hormonal Pharmacotherapy, and Personalized Strategies in Premature Ovarian Insufficiency and Iatrogenic Forms

    International Journal of Drug Delivery Technology

  6. Fezolinetant decreases vasomotor symptoms in humans (menopausal vasomotor symptoms).

    “demonstrate reduced frequency of vasomotor symptoms with their use”

    Reviewmenopausal vasomotor symptomsfemales

    Where do neurokinin receptor antagonists fit into management of menopausal vasomotor symptoms?

    JAAPA : official journal of the American Academy of Physician Assistants

  7. Fezolinetant improves vasomotor symptoms in patients without a history of breast cancer.

    “Fezolinetant is a novel neurokinin 3 receptor antagonist that has demonstrated clinical benefit in patients without a history of breast cancer.”

    Reviewin patients without a history of breast cancer

    Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies

    Expert review of clinical pharmacology

  8. Fezolinetant improves vasomotor symptoms in humans (moderate-to-severe VMS).

    “Recent three randomized clinical trials (RCTs), including SKYLIGHT 1,2, and 4 confirmed the safety and efficacy for treating moderate-to-severe VMS women.”

    Reviewmoderate-to-severe VMSfemales

    Menopause part I: Vasomotor symptoms (I)

    Taiwanese journal of obstetrics & gynecology

  9. Fezolinetant improves vasomotor symptoms in humans (menopause).

    “In 2023, the FDA approved fezolinetant, the first selective NK3R antagonist, for the treatment of moderate to severe VMS associated with menopause.”

    Reviewmenopause

    A New Hope for Woman with Vasomotor Symptoms: Neurokinin B Antagonists

    Journal of clinical medicine

Vasomotor symptoms

downin humans6downin reviews1−60% vms

7 studies
  1. Fezolinetant decreases vasomotor symptoms in humans (postmenopausal women; compared with placebo) (60% to 70% reduction in VMS intensity).

    “Fezolinetant was shown to be effective and safe in reducing the frequency and severity of vasomotor symptoms (VMS) compared with placebo in postmenopausal women.”

    Reviewpostmenopausal women; compared with placebofemales

    Fezolinetant: neurokinin 3 (NK3) receptor antagonist for the treatment of menopausal vasomotor symptoms

    Universitas Médica

  2. Fezolinetant decreases vasomotor symptoms (60% decrease in VMS).

    “Non-hormonal Neurokini3 antagonists like fezolinetant, decreased VMS by 60% and benefited high-risk patients.”

    Review

    Innovative Drug Delivery Systems for Management of Menopausal Symptoms: A Systematic Review

    International journal of women's health

  3. Fezolinetant decreases vasomotor symptoms in humans (menopause) (50%-65% reduction).

    “NK3R antagonists (fezolinetant, 50%-65% VMS reduction)”

    Reviewmenopausefemales

    Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management

    Frontiers in reproductive health

  4. Fezolinetant decreases vasomotor symptoms in humans (postmenopausal women).

    “Emerging treatments like fezolinetant demonstrate promise in reducing VMS by addressing the underlying pathophysiology”

    Reviewpostmenopausal womenfemales

    Treatment of Menopausal Symptoms When Hormone Therapy Is Contraindicated

    Seminars in reproductive medicine

  5. Fezolinetant decreases vasomotor symptoms in humans (menopause).

    “Fezolinetant has shown efficacy in reducing the frequency and severity of VMS”

    Reviewmenopause

    Pharmacokinetic evaluation of fezolinetant for the treatment of vasomotor symptoms caused by menopause

    Expert opinion on drug metabolism & toxicology

  6. Fezolinetant decreases vasomotor symptoms in menopausal women.

    “NK3R antagonists provide a safe and effective treatment option for managing menopausal women with VMS.”

    Reviewin menopausal women

    Non-hormonal pharmacological interventions for managing vasomotor symptoms-how can we help: 2024 landscape

    European journal of obstetrics, gynecology, and reproductive biology

  7. Fezolinetant decreases vasomotor symptoms in humans (associated with menopause; compared with placebo).

    “Clinical trials have demonstrated fezolinetant is superior to placebo in decreasing the frequency and severity of vasomotor symptoms.”

    Reviewassociated with menopause; compared with placebo

    Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms

    The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

More on Vasomotor symptoms

Vasomotor symptom frequency

downin humans3no changein humans1

3 studies
  1. Fezolinetant decreases vasomotor symptom frequency in humans (moderate to severe vasomotor symptoms associated with menopause; versus placebo) (Week 12 least squares mean difference −2.51 (95% CI −3.20 to −1.82)).

    “reductions in VMS frequency for fezolinetant 45 mg versus placebo were - 1.46 (-2.01, -0.92) and - 2.51 (-3.20, -1.82).”

    Human trialmoderate to severe vasomotor symptoms associated with menopause; versus placebo45 mg12 weeksassigned female at births

    Early onset, maintenance of effect, and day-/night-time findings following fezolinetant treatment for moderate to severe vasomotor symptoms associated with menopause: A pooled phase 3 analysis

    Maturitas

  2. Fezolinetant decreases vasomotor symptom frequency in humans (menopause; compared with other nonhormone therapies).

    “Fezolinetant has been shown to result in a significant reduction in vasomotor symptom frequency when compared to other nonhormone therapies”

    Reviewmenopause; compared with other nonhormone therapies

    Cooling the flames: Navigating menopausal vasomotor symptoms with nonhormone medications

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

  3. Fezolinetant showed no clear effect on vasomotor symptom frequency in humans (Postmenopausal women; compared with 27 hormone therapy regimens).

    “Changes in VMS frequency did not differ significantly between fezolinetant 45 mg and any of the 27 HT regimens studied.”

    ReviewPostmenopausal women; compared with 27 hormone therapy regimens45 mg12 weeksfemales

    Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause

    Menopause (New York, N.Y.)

  4. Fezolinetant decreases vasomotor symptom frequency in humans (Postmenopausal women; compared with other nonhormone therapies).

    “Fezolinetant 45 mg once daily was statistically significantly more effective than other non-HTs in reducing the frequency of moderate to severe VMS.”

    ReviewPostmenopausal women; compared with other nonhormone therapies45 mg once daily12 weeksfemales

    Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause

    Menopause (New York, N.Y.)

Sleep disturbance

upin humans1downin humans1

2 studies
  1. Fezolinetant improves sleep disturbance in humans (LS mean difference -1.31, 95% CI -2.59, -0.02).

    “Fezolinetant 30 mg and 45 mg improved sleep disturbance over the past 7 days (PROMIS SD-SF-8b total score) from baseline to 12 weeks versus placebo.”

    Human trial45 mg12 weeksn = 648

    Effect of fezolinetant on sleep, health-related quality of life and work productivity

    Climacteric : the journal of the International Menopause Society

  2. Fezolinetant improves sleep disturbance in humans (moderate to severe vasomotor symptoms due to menopause).

    “Fezolinetant 30 mg and 45 mg improved sleep disturbance and impairment versus placebo at 12 weeks”

    Human trialmoderate to severe vasomotor symptoms due to menopause12 weeks

    Effect of fezolinetant on sleep, health-related quality of life and work productivity

    Climacteric : the journal of the International Menopause Society

  3. Fezolinetant decreases sleep disturbance in humans (Menopause; unsuitable for hormone therapy; compared with placebo) (PROMIS SD-SF 8b total score difference -2.5, 95% CI -3.9 to -1.1; P<0.001).

    “At week 24, the fezolinetant group had a greater reduction in sleep disturbance (PROMIS SD-SF 8b total score) compared with placebo”

    Human trialMenopause; unsuitable for hormone therapy; compared with placebo45 mg once daily24 weeksn = 452

    Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial

    BMJ (Clinical research ed.)

Vasomotor symptom frequency and severity

downin humans2

2 studies
  1. Fezolinetant decreases vasomotor symptom frequency and severity in humans (menopause; compared with placebo).

    “The studies demonstrated that both drugs significantly reduce the frequency and severity of vasomotor symptoms compared with placebo”

    Reviewmenopause; compared with placebofemales

    Neurokinin receptor antagonists in the treatment of menopausal vasomotor symptoms: Efficacy, safety, and impact on sleep and quality of life

    Research Society and Development

  2. Fezolinetant decreases vasomotor symptom frequency and severity in humans (postmenopause).

    “fezolinetant, a neurokinin-3 receptor antagonist and elinzanetant, a neurokinin-1-3 receptor antagonist, diminish the frequency and severity of vasomotor symptoms.”

    Reviewpostmenopausefemales

    Neurokinin Antagonists to Treat Vasomotor Symptoms-Possible Implications for Long-Term Health and Disease

    Journal of clinical medicine

Quality of life

upin humans2

2 studies
  1. Fezolinetant improves quality of life in humans (postmenopausal women).

    “It also improves quality of life and sleep disturbances, with an adequate safety profile.”

    Reviewpostmenopausal womenfemales

    Fezolinetant: neurokinin 3 (NK3) receptor antagonist for the treatment of menopausal vasomotor symptoms

    Universitas Médica

  2. Fezolinetant improves quality of life in humans (menopause).

    “with a positive impact on sleep- and health-related QoL and acceptable safety and tolerability profile.”

    Reviewmenopause

    Pharmacokinetic evaluation of fezolinetant for the treatment of vasomotor symptoms caused by menopause

    Expert opinion on drug metabolism & toxicology

Work productivity loss

downin humans1

1 study
  1. Fezolinetant decreases work productivity loss in population 1 (22.6 vs 6.3 percentage points).

    “After 1 year of treatment with fezolinetant or placebo, overall work productivity loss improved by 22.6 and 6.3 percentage points, respectively, in population 1 and by 22.5 and 9.8 percentage points, respectively, in population 2.”

    Human trialin population 11 year

    Estimated impact of fezolinetant versus placebo on work productivity and indirect costs among women experiencing vasomotor symptoms associated with menopause

    Menopause (New York, N.Y.)

  2. Fezolinetant decreases work productivity loss in humans (post hoc analysis of SKYLIGHT 1, SKYLIGHT 2, and DAYLIGHT trials) (-12.4% (population 1), -10.2% (population 2)).

    “Overall work productivity loss improved with fezolinetant versus placebo (population 1: -12.4% [ P <0.0001]; population 2: -10.2% [ P <0.0001]).”

    Human trialpost hoc analysis of SKYLIGHT 1, SKYLIGHT 2, and DAYLIGHT trials52 weeksfemales

    Estimated impact of fezolinetant versus placebo on work productivity and indirect costs among women experiencing vasomotor symptoms associated with menopause

    Menopause (New York, N.Y.)

Thermotaxis behavior

upin worms1

1 study
  1. Fezolinetant improves thermotaxis behavior in worms (nlp-58 overexpression).

    “partially improved the thermotaxis defect caused by nlp-58 overexpression.”

    Model organismsnlp-58 overexpression

    Tachykinin-like NLP-58 signaling through TKR-1 modulates thermotaxis behavior in Caenorhabditis elegans

    PLoS genetics

Menopausal vasomotor symptoms

downin humans1

1 study
  1. Fezolinetant decreases menopausal vasomotor symptoms in humans (MHT contraindicated or not preferred).

    “non-hormonal drugs, such as paroxetine, fezolinetant and elinzanetant, offer effective alternative treatment options.”

    ReviewMHT contraindicated or not preferred

    Hormonal therapies are still first-line for menopausal vasomotor symptoms, but novel non-hormonal drugs are promising

    Drugs & Therapy Perspectives

More on Menopausal vasomotor symptoms

Hot flash frequency

downin humans1−21% reduction after accounting for placebo response

1 study
  1. Fezolinetant decreases hot flash frequency in humans (menopausal hot flashes) (20.6% reduction after accounting for placebo response).

    “At the recommended doses, fezolinetant (45 mg) and elinzanetant (120 mg) achieved reductions of 20.6% and 19.6%, respectively.”

    Reviewmenopausal hot flashes45 mgfemales

    Quantitative assessment of neurokinin receptor antagonists in menopausal hot flashes: a model-based meta-analysis

    Menopause (New York, N.Y.)

Depression

downin humans1

1 study
  1. Fezolinetant decreases depression in humans (associated with menopause).

    “Participants taking fezolinetant also had greater improvements in sleep, quality of life, depression, and work productivity.”

    Human trialassociated with menopausepill6 monthsfemales

    Fezolinetant treatment for hot flashes associated with menopause: A plain language summary of the DAYLIGHT study

    Women's health (London, England)

More on Depression

Hot flashes

downin humans1

1 study
  1. Fezolinetant decreases hot flashes in humans (associated with menopause).

    “Compared with the placebo, fezolinetant reduced the number of hot flashes that participants had each day.”

    Human trialassociated with menopausepill6 monthsfemales

    Fezolinetant treatment for hot flashes associated with menopause: A plain language summary of the DAYLIGHT study

    Women's health (London, England)

More on Hot flashes

Missed work hours

downin humans1

1 study
  1. Fezolinetant decreases missed work hours in population 1 (2.8 to 4.2 work hours per week per woman).

    “Overall, this corresponded to an increase of 2.8 to 4.2 work hours per week per woman treated with fezolinetant versus placebo in population 1.”

    Human trialin population 11 year

    Estimated impact of fezolinetant versus placebo on work productivity and indirect costs among women experiencing vasomotor symptoms associated with menopause

    Menopause (New York, N.Y.)

Treatment-emergent adverse events

no changein humans1

1 study
  1. Fezolinetant showed no clear effect on treatment-emergent adverse events in humans (Menopause; unsuitable for hormone therapy; compared with placebo) (TEAEs: 65.0% versus 61.1%; serious TEAEs: 4.4% versus 3.5%).

    “Both groups showed similar incidences of treatment emergent adverse events”

    Human trialMenopause; unsuitable for hormone therapy; compared with placebo45 mg once daily24 weeksn = 452

    Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial

    BMJ (Clinical research ed.)

Daily frequency of moderate-severe vasomotor symptoms

downin humans1

1 study
  1. Fezolinetant decreases daily frequency of moderate-severe vasomotor symptoms in humans (Menopause; unsuitable for hormone therapy; compared with placebo) (Least squares mean difference -1.93, 95% CI -2.64 to -1.22).

    “At week 24, fezolinetant significantly reduced the frequency (least squares mean difference -1.93, 95% confidence interval (CI) -2.64 to -1.22; P<0.001)”

    Human trialMenopause; unsuitable for hormone therapy; compared with placebo45 mg once daily24 weeksn = 452

    Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial

    BMJ (Clinical research ed.)

All 21

What is fezolinetant linked with?

10

Studies link fezolinetant with 10 measures, among them non-benign neoplasms, nightmare and gamma-glutamyltransferase.

Non-benign neoplasms

upin humans1RR 6.6

1 study
  1. Fezolinetant is associated with non-benign neoplasms in humans (Licensed-dose comparison with placebo in the SKYLIGHT phase III programme) (RR 6.6 (95% CI 0.9–51.3)).

    “giving a relative risk at the licensed dose of 6.6 (95% confidence interval 0.9-51.3)”

    ReviewLicensed-dose comparison with placebo in the SKYLIGHT phase III programme45 mg

    Reassessing the Neoplasm Signal with Fezolinetant: Regulatory Inference, Mechanistic Plausibility, and the Case for Proactive Pharmacovigilance

    Drug safety

More on Non-benign neoplasms

Nightmare

upin humans1

1 study
  1. Fezolinetant is associated with nightmare in humans (primary suspect drug in FAERS) (ROR 6.61 (95% CI 3.90-11.19)).

    “Nightmare (ROR 6.61, 95% CI(ROR): 3.90-11.19, PRR 6.56, 95%CI(PRR): 3.89-11.06) was detected as a potential novel safety signal”

    Humansprimary suspect drug in FAERS

    Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database

    Naunyn-Schmiedeberg's archives of pharmacology

Gamma-glutamyltransferase

upin humans1

1 study
  1. Fezolinetant is associated with gamma-glutamyltransferase in humans (primary suspect drug in FAERS) (ROR 33.58 (95% CI 24.39-46.22)).

    “gamma-glutamyltransferase increased (ROR 33.58, 95% CI(ROR): 24.39-46.22, PRR 32.86, 95% CI(PRR): 24.04-44.91)”

    Humansprimary suspect drug in FAERS

    Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database

    Naunyn-Schmiedeberg's archives of pharmacology

More on Gamma-glutamyltransferase

Aspartate aminotransferase

upin humans1

1 study
  1. Fezolinetant is associated with aspartate aminotransferase in humans (primary suspect drug in FAERS) (ROR 41.72 (95% CI 34.97-49.76)).

    “aspartate aminotransferase increased (ROR 41.72, 95%CI(ROR): 34.97-49.76, PRR 38.57, 95%CI(PRR): 32.77-45.39)”

    Humansprimary suspect drug in FAERS

    Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database

    Naunyn-Schmiedeberg's archives of pharmacology

More on Aspartate aminotransferase

Alanine aminotransferase

upin humans1

1 study
  1. Fezolinetant is associated with alanine aminotransferase in humans (primary suspect drug in FAERS) (ROR 48.31 (95% CI 41.34-56.46)).

    “alanine aminotransferase increased (ROR 48.31, 95%CI(ROR): 41.34-56.46, PRR 43.49, 95% CI(PRR): 37.80-50.04)”

    Humansprimary suspect drug in FAERS

    Real-world safety profile of fezolinetant: a disproportionality analysis based on the FAERS database

    Naunyn-Schmiedeberg's archives of pharmacology

More on Alanine aminotransferase

Nonbenign neoplasms

upin reviews1

1 study
  1. Fezolinetant raises the risk of nonbenign neoplasms (menopausal vasomotor symptoms).

    “emerging data from meta-analysis and pooled analysis consistently showed a significant increase in the risk of nonbenign neoplasms”

    Reviewmenopausal vasomotor symptoms

    Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications

    Journal of the Endocrine Society

More on Nonbenign neoplasms

Drug-induced liver injury

upin silico1

1 study
  1. Fezolinetant raises the risk of drug-induced liver injury in DILIsym simulations.

    “DILIsym simulations indicated a dose-dependent relationship between fezolinetant exposure and hepatotoxicity primarily caused by electron transport chain inhibition.”

    In silicoin DILIsym simulations

    Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant

    Clinical pharmacology and therapeutics

More on Drug-induced liver injury

Treatment-emergent adverse events

upin humans1

1 study
  1. Fezolinetant is associated with treatment-emergent adverse events in humans (compared with placebo in women with vasomotor symptoms due to menopause) (62.9% versus 55.3% with placebo).

    “TEAEs occurred in 55.3%, 62.9%, and 65.4%, respectively; exposure-adjusted results were consistent with these results.”

    Reviewcompared with placebo in women with vasomotor symptoms due to menopause45 mgfemalesn = 1,100

    Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies

    Advances in therapy

Liver transaminases

upin humans1

1 study
  1. Fezolinetant is associated with liver transaminases in humans.

    “Common adverse effects associated with the use of fezolinetant include headache and gastrointestinal disturbances, as well as elevations in liver transaminase levels.”

    Review

    Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms

    The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

More on Liver transaminases

Headache and gastrointestinal disturbances

upin humans1

1 study
  1. Fezolinetant is associated with headache and gastrointestinal disturbances in humans.

    “Common adverse effects associated with the use of fezolinetant include headache and gastrointestinal disturbances, as well as elevations in liver transaminase levels.”

    Review

    Fezolinetant: A New Nonhormonal Treatment for Vasomotor Symptoms

    The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

More on Headache and gastrointestinal disturbances

Has fezolinetant been tested in people?

16 of 25 about aging

Yes: 9 trials and 1 observational study in people have been published, and 24 trials are registered.

Approved

  • FDA Veozah

    May 12, 2023Menopause, vasomotor symptoms, vasomotor symptoms due to menopause, moderate-to-severe vasomotor symptoms

  • EMA Veoza

    Dec 7, 2023Menopause, Hot Flashes, vasomotor symptoms, moderate to severe vasomotor symptoms associated with menopause

Repurposing

Every condition in trials

  • Menopause hot flashes

    Phase 2/3Recruiting1 trial

  • Menopause related conditions

    Phase 2/3Recruiting1 trial

  • Prostatic neoplasm

    Phase 2Recruiting3 trials

Who is developing fezolinetant?

3 companies: Astellas Pharma, Astellas Pharma Global Development and Astellas Pharma China.

Companies
  • Astellas PharmaPhase 3hot flashes
  • Astellas Pharma Global DevelopmentPhase 3hot flashes, vasomotor symptoms
  • Astellas Pharma ChinaPhase 3hot flashes

Trial sponsors

Funding

1 grant since 2025

Swiss National Science FoundationCHF 4.9K

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 2Feb 2026: 1Mar 2026: 4Apr 2026: 4May 2026: 3Jun 2026: 1Jul 2026: 1Aug 2026: 2Sep 2026: 1Oct 2026: 10Nov 2026: 434 papers in 12 months

See all 60 papers on fezolinetant